Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...
Eugene Lucas, MD, is a board-certified obesity medicine specialist at the Weill Cornell Medicine Comprehensive Weight Control Center. He provides comprehensive care to help his patients increase both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results